RP-59500, A NEW STREPTOGRAMIN HIGHLY-ACTIVE AGAINST RECENT ISOLATES OF NORTH-AMERICAN STAPHYLOCOCCI

被引：29

作者：

ARCHER, GL

AUGER, P

DOERN, GV

FERRARO, MJ

FUCHS, PC

JORGENSEN, JH

LOW, DE

MURRAY, PR

RELLER, LB

STRATTON, CW

WENNERSTEN, CB

MOELLERING, RC

机构：

[1] NEW ENGLAND DEACONESS HOSP, DEPT MED, BOSTON, MA 02215 USA

[2] DUKE UNIV, MED CTR, DURHAM, NC 27710 USA

[3] VANDERBILT UNIV, MED CTR, NASHVILLE, TN 37240 USA

[4] BARNES HOSP, ST LOUIS, MO 63110 USA

[5] INST CARDIOL MONTREAL, MONTREAL H1T 1C8, QUEBEC, CANADA

[6] MED CTR HOSP, SAN ANTONIO, TX USA

[7] MT SINAI HOSP, TORONTO M5G 1X5, ONTARIO, CANADA

[8] VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, RICHMOND, VA 23298 USA

[9] UNIV MASSACHUSETTS, MED CTR, WORCESTER, MA 01605 USA

[10] MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA

[11] ST VINCENTS HOSP & MED CTR, PORTLAND, OR USA

来源：

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 1993年 / 16卷 / 03期

关键词：

D O I：

10.1016/0732-8893(93)90113-L

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

To assess the potential clinical utility of RP 59500, 10 investigators from separate locations in the United States and Canada each tested approximately 200 current isolates of staphylococci (Staphylococcus aureus and coagulase-negative staphylococci) by a standard protocol. RP 59500 was highly active (MIC90 less-than-or-equal-to 2 mug/ml) against all strains, including those that were resistant to oxacillin, ciprofloxacin, erythromycin, and spiramycin.

引用

页码：223 / 226

页数：4

共 8 条

[1] INVITRO ANTISTAPHYLOCOCCAL ACTIVITY AND TESTING OF RP-59500, A NEW STREPTOGRAMIN, BY 2 METHODS
ALDRIDGE, KE
SCHIRO, DD
VARNER, LM
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (04) : 854 - 855
[2] BARRIERE JC, 1992, J ANTIMICROB CHEMOTH, V30, P1
[3] INVITRO AND INVIVO SYNERGIC ACTIVITY AND FRACTIONAL INHIBITORY CONCENTRATION (FIC) OF THE COMPONENTS OF A SEMISYNTHETIC STREPTOGRAMIN, RP 59500
BOUANCHAUD, DH
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 30 : 95 - 99
[4] A PHASE-I, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE TOLERANCE AND PHARMACOKINETIC BEHAVIOR OF RP 59500
ETIENNE, SD
MONTAY, G
LELIBOUX, A
FRYDMAN, A
GARAUD, JJ
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 30 : 123 - 131
[5] INVITRO ACTIVITY OF RP-59500, A SEMISYNTHETIC INJECTABLE PRISTINAMYCIN, AGAINST STAPHYLOCOCCI, STREPTOCOCCI, AND ENTEROCOCCI
FASS, RJ
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (03) : 553 - 559
[6] MAPLE PAC, 1989, LANCET, V1, P537
[7] INVITRO SUSCEPTIBILITY OF ORAL STREPTOCOCCI TO PRISTINAMYCIN
MASKELL, JP
WILLIAMS, JD
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1987, 19 (05) : 585 - 590
[8] 1990, NCCLS M7A2 NAT COMM

← 1 →